7-Keto Fuel
  • Improve lean body mass and reduce waist line

  • Increase thermogenisis or your body's ability to burn calories


Retail Price: $35.99
Our Price:$30.99
Add to Cart
Description

7-KETO DHEA is a naturally occurring metabolite derived from DHEA (Dehydroepiandrosterone). It can be found in many of our body tissues but cannot be converted to active androgens (testosterone) and estrogens. 7-KETO DHEA is more potent than other DHEA.

As part of an exercise program, 7-KETO DHEA may improve lean body mass and enable the body to build muscle in a growth promoting environment. 7-Keto DHEA has also been shown to increase thermogenesis, or your body's ability to burn calories. Give your training efforts a boost with this non-hormonal, non-androgenic derivative of DHEA.

When we age the ability to control our quality of life becomes an issue for all of us. The application of aging research into the steroid dehydroepiandrosterone (DHEA) has helped our understanding of age induced losses of functional capacity, and has subsequently lead to the discovery of a relatively new compound "7-OXO-DHEA".

7 - Keto as it is more commercially known may have physiological actions that allow us to train well into old age. Recent studies suggest it may also have applications to a youthful, healthy, and physically active population. So the questions beckon; is there evidence to support 7-keto use over a broad spectrum of ages? And if so, how can it affect our physiques? (Please see research below)

Supplement Facts

Serving Size: 2 Capsules
Servings Per Container: 15

Amount Per Serving:

7-Keto: 100mg
(3-acetyl-7-Oxo-Dehydroeplandosterone)

Research

"A Randomized, Double-Blind, Placebo Controlled Study of 3-Acetyl-7-Oxo-Dehydroepiandrosterone in Healthy Overweight Adults," Kalman, DS., Colker, CM., Swain, MA., Torina, GC., Shi, Q. Current Therapeutics, (7):435-442 2000

Objective:
The purpose of this study was to determine the effects of 3-acetyl-7-oxo-dehydroepiandrosterone (7-oxo-DHEA) in healthy overweight adults. Methods: In a double-blind, placebo-controlled protocol, 30 adults (28 women and 2 men; mean age, 44.5 @+ 11.5 years) with a mean body mass index of 31.9 @+ 6.2 kg/m^2 were randomly divided into 2 groups of 15: Group 1 received 7-oxo-DHEA 100 mg twice daily and Group 2 received placebo for 8 weeks. All subjects participated in an exercise training program 3 times per week. Each exercise session consisted of 60 minutes of cross-training (aerobic and anaerobic exercise) under the supervision of an exercise physiologist. In addition, each subject was instructed to follow a diet of @O 1800 kcal/d (20 kcal/[kg @. d]) by a registered dietician. Subjects received biweekly dietary counselling to encourage compliance. Study participants underwent serum multiple-assay chemistry testing, as well as body composition, blood pressure, and dietary analysis at baseline, week 4, and week 8.

Results:

Of the 30 subjects who entered the study, 23 completed the 8-week protocol. Seven subjects dropped out for personal reasons unrelated to the study. Group 1 lost a significant amount of body weight compared with Group 2 (-2.88 kg vs -0.97 kg; P = 0.01) over the 8 weeks. Group 1 also achieved a significant reduction in body fat compared with Group 2 (-1.8% vs -0.57%; P = 0.02). The rate of change in body fat per 4-week interval in Group 1 was 3.1 times that in Group 2 (-0.88% vs -0.28%; P < 0.01). Group 1 also experienced a significant increase in triiodothyronine (T3) levels compared with Group 2 over the 8-week study period (+17.88 ng/dL vs 2.75 ng/dL; P = 0.04). There were no significant changes in levels of thyroid-stimulating hormone (TSH) or thyroxine (T4) in either group. In addition, no significant changes were observed in vital signs, blood sugar, testosterone and estradiol levels, liver and renal function, or overall caloric intake during the study. No subjective adverse effects were reported throughout the study.

 

Zenk J, Helmer T, Kassen L, et al. The effects of NaturaLean on weight loss: A randomised, double blind, placebo controlled Trial. Curr Ther Res. 2002;63:263-272.

This study evaluated whether a commercial weight-loss product (Lean System 7) would result in less reduction in resting metabolic rate (RMR) in overweight subjects on a calorie-restricted diet and exercise regimen than in subjects using diet and exercise alone.

Methods

In this randomized, double-blind, placebo-controlled study, healthy overweight adults were given three capsules of a commercial weight-loss product twice daily or an identical placebo and followed a calorie-restricted diet and an exercise program for 8 wk. RMR, body weight, body mass index, waist and hip circumferences, and body composition by dual-energy x-ray absorptiometry were measured at baseline and week 8. An intention-to-treat analysis was performed.

Results

Of 47 adults enrolled, 35 completed the study. Subjects taking the commercial weight-loss product had a significant (P = 0.03) increase in RMR, 7.2% increase versus 0.7% decrease in the placebo group. Subjects taking the commercial weight-loss product also had a significant (P = 0.04) decrease in hip circumference, 3.78 cm versus 2.07 cm in the placebo group. There were no other statistically significant differences in any other outcome variable, diet composition, exercise compliance, or adverse events.

Conclusion

The results of this study showed that administration of a commercial weight-loss product to overweight adults in conjunction with a calorie-restricted diet and moderate exercise program effectively reverses the decrease in RMR associated with calorie restriction within this study population. The commercial weight-loss product was well tolerated, and there were no serious adverse events over the 8 wk studied

Relevant Studies

Kalman DS, Colker CM, Swain MA, et al. A randomized, double-blind, placebo controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy overweight adults. Curr Ther Res. 2000;61:435-442.

Zenk J, Helmer T, Kassen L, et al. The effects of NaturaLean on weight loss: A randomised, double blind, placebo controlled Trial. Curr Ther Res. 2002;63:263-272.